Skip to content

Efficacy of Mizoribine for Children with Henoch-Schnlein Purpura Nephritis Presenting with Nephrotic Range Proteinuria: A Prospective and Controlled Study in China

Efficacy of Mizoribine for Children with Henoch-Schnlein Purpura Nephritis Presenting with Nephrotic Range Proteinuria: A Prospective and Controlled Study in China

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPC-16008619
Enrollment
Unknown
Registered
2016-06-09
Start date
2016-07-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children with Henoch-Sch?nlein Purpura Nephritis

Interventions

mizoribine:5 mg/kg body weight daily (maximum total dose: 150 mg)

Sponsors

Nanjing General Hospital of Nanjing Military Command
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. HSPN patients with moderate proteinuria (grade IIb and IIIa)(2550mg/kg/d/24 h proteinuria); 2. HSPN patients with nephrotic syndrome (grade?b and ?) (>50mg/kg/d/24 h proteinuria); 3. Male or female patient between 5 and 18 years age; 4. Patient who have participated any drug study within 3 months prior to screening; 5. Patients who sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. HSPN patients with grade IV or V disease; 2. Patient with IgA nephritis, thrombocytopenia purpura and systemic lupus erythematosus; 3. Patient with Ccr > 30 umol/L; 4. Patient who had history of allergy to MZR; 5. Patient with white blood cell count 420 mol/L, and if patient who have received the treatment of allopurinol (daily 8mg/kg, 2-3 times a day) for 2 weeks, patient who can not be reduced to < 420 mmol/L; 8. Patient who had received immunosuppressant (Cyclophosphamide, Tripterygium wilfordii (Chinese traditional medicine), Mycophenolate mofetil, Azathioprine and Tacrolimus, etc.) with immunosuppressive effect within 2 weeks prior to screening; 9. Patient who is unsuitable for participating in this study in the opinion of investigators.

Design outcomes

Primary

MeasureTime frame
Total Remission Rate = Complete remission rate+Partial remission rate;Total Remission Rate;Partial remission rate;

Secondary

MeasureTime frame
reducing effect of proteinuria;reducing effect of steroid;Assessment of the changes and percentage change of Serum albumin, serum creatinine, eGFR, Cholesterol, triglyceride, hematuria, ß-N-acetylglucosaminidase, C reactive protein and uric acid from the baseline;

Countries

China

Contacts

Public ContactZhengkun Xia

Nanjing General Hospital of Nanjing Military Command

njxzk@126.com+86 18951011163

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026